Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Krum

Showing results (71-80 of 421) with videos related to

Pageof 43
Sort By:
Heart Failure Monitor|March 14, 2003
Should patients with chronic heart failure be treated with "statins"?Emma Ashton, Danny Liew, Henry Krum
Cardiovascular Therapeutics|April 20, 2010
Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?Pornwalee Porapakkham, Pramote Porapakkham, Henry Krum
Current Heart Failure Reports|June 3, 2009
Pharmacologic management of the cardiorenal syndrome in heart failureHenry Krum, Pupalan Iyngkaran, Suree Lekawanvijit
Current Cardiology Reports|September 24, 2013
How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?Kui Toh Gerard Leong, Henry Krum
European Journal of Heart Failure|November 13, 2012
Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythmIngrid Hopper, Marina Skiba, Henry Krum
Nature Reviews. Cardiology|September 30, 2015
New medical therapies for heart failureThomas G von Lueder, Henry Krum
International Journal of Cardiology|December 3, 2014
Neprilysin inhibitors preserve renal function in heart failureFiona Bodey, Ingrid Hopper, Henry Krum
American Journal of Physiology. Renal Physiology|May 6, 2016
Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndromeSuree Lekawanvijit, Andrew R Kompa, Henry Krum
Clinical Cardiology|April 12, 2008
A comparison of the aldosterone-blocking agents eplerenone and spironolactoneAllan Struthers, Henry Krum, Gordon H Williams
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 29, 2006
The impact of baseline HR and BP on the tolerability of carvedilol in the elderly: the COLA (Carvedilol Open Label Assessment) II StudyPeter S Macdonald, Julie Hill, Henry Krum, et al.
Pageof 43

Showing results (71-80 of 421) with videos related to

Sort By:
Pageof 43
Heart Failure Monitor|March 14, 2003
Should patients with chronic heart failure be treated with "statins"?Emma Ashton, Danny Liew, Henry Krum
Cardiovascular Therapeutics|April 20, 2010
Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?Pornwalee Porapakkham, Pramote Porapakkham, Henry Krum
Current Heart Failure Reports|June 3, 2009
Pharmacologic management of the cardiorenal syndrome in heart failureHenry Krum, Pupalan Iyngkaran, Suree Lekawanvijit
Current Cardiology Reports|September 24, 2013
How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?Kui Toh Gerard Leong, Henry Krum
European Journal of Heart Failure|November 13, 2012
Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythmIngrid Hopper, Marina Skiba, Henry Krum
Nature Reviews. Cardiology|September 30, 2015
New medical therapies for heart failureThomas G von Lueder, Henry Krum
International Journal of Cardiology|December 3, 2014
Neprilysin inhibitors preserve renal function in heart failureFiona Bodey, Ingrid Hopper, Henry Krum
American Journal of Physiology. Renal Physiology|May 6, 2016
Protein-bound uremic toxins: a long overlooked culprit in cardiorenal syndromeSuree Lekawanvijit, Andrew R Kompa, Henry Krum
Clinical Cardiology|April 12, 2008
A comparison of the aldosterone-blocking agents eplerenone and spironolactoneAllan Struthers, Henry Krum, Gordon H Williams
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 29, 2006
The impact of baseline HR and BP on the tolerability of carvedilol in the elderly: the COLA (Carvedilol Open Label Assessment) II StudyPeter S Macdonald, Julie Hill, Henry Krum, et al.
Pageof 43